Información de Savara Inc, dividendo de Savara Inc, actividades de los accionistas y más

Más Datos de Savara Inc Compañía

Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Información de Savara Inc



Símbolo de cotizaciónSVRA

Nombre de la empresaSavara Inc

Fecha de salida a bolsaJun 25, 2001

Director ejecutivoMr. Matthew (Matt) Pauls, J.D.

Número de empleados59

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 25

Dirección6836 Bee Cave Road

CiudadAUSTIN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal78746

Teléfono151285113796

Sitio Webhttps://savarapharma.com/

Símbolo de cotizaciónSVRA

Fecha de salida a bolsaJun 25, 2001

Director ejecutivoMr. Matthew (Matt) Pauls, J.D.

Ejecutivos de Savara Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. David A. Ramsay

Independent Director

2.47M

-0.70%

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

220.84K

+4.74%

Ms. Anne Erickson

Chief Business Officer

194.99K

+72.18%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+23.53%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

101.74K

+64.79%

Mr. Nevan Charles Elam, J.D.

Independent Director

--

Mr. Richard J. (Rick) Hawkins

Independent Director

--

Mr. David L. Lowrance, CPA

Chief Financial and Administrative Officer, Secretary

--

Mr. Matthew (Matt) Pauls, J.D.

Chairman of the Board, Chief Executive Officer

--

Dr. Raymond Dennis (Ray) Pratt, M.D.

Chief Medical Officer

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. David A. Ramsay

Independent Director

2.47M

-0.70%

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

220.84K

+4.74%

Ms. Anne Erickson

Chief Business Officer

194.99K

+72.18%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+23.53%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

101.74K

+64.79%

Mr. Nevan Charles Elam, J.D.

Independent Director

--

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: dom., 2 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

New Enterprise Associates (NEA)

12.44%

Bain Capital Life Sciences Investors, LLC

8.95%

Deerfield Management Company, L.P.

6.90%

TCG Crossover Management, LLC

6.29%

Frazier Life Sciences Management, L.P.

5.83%

Otro

59.59%

Accionistas

Proporción

New Enterprise Associates (NEA)

12.44%

Bain Capital Life Sciences Investors, LLC

8.95%

Deerfield Management Company, L.P.

6.90%

TCG Crossover Management, LLC

6.29%

Frazier Life Sciences Management, L.P.

5.83%

Otro

59.59%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

29.98%

Hedge Fund

20.01%

Venture Capital

18.26%

Investment Advisor/Hedge Fund

14.30%

Private Equity

5.83%

Corporation

3.46%

Individual Investor

2.45%

Research Firm

0.47%

Bank and Trust

0.27%

Otro

4.97%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

286

169.85M

86.94%

-21.45M

2025Q2

295

181.81M

105.19%

-8.48M

2025Q1

306

176.74M

102.29%

-9.64M

2024Q4

294

173.80M

101.27%

-5.45M

2024Q3

274

169.68M

103.28%

+3.87M

2024Q2

257

157.29M

95.89%

+28.15M

2024Q1

230

131.01M

94.21%

-92.17K

2023Q4

197

123.19M

91.03%

-2.15M

2023Q3

177

120.11M

89.27%

+14.67M

2023Q2

170

92.45M

81.05%

-2.68M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

New Enterprise Associates (NEA)

24.47M

14.16%

--

Jun 30, 2025

Bain Capital Life Sciences Investors, LLC

17.60M

10.18%

--

Jun 30, 2025

Deerfield Management Company, L.P.

7.96M

4.61%

--

Jun 30, 2025

TCG Crossover Management, LLC

12.36M

7.15%

--

Jun 30, 2025

Frazier Life Sciences Management, L.P.

11.46M

6.63%

--

Jun 30, 2025

Vestal Point Capital, LP

11.02M

6.37%

+15.00K

+0.14%

Jun 30, 2025

VR Adviser, LLC

8.88M

5.14%

+5.63M

+172.72%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.54M

4.94%

-164.33K

-1.89%

Jun 30, 2025

Nantahala Capital Management, LLC

8.33M

4.82%

+250.00K

+3.10%

Jun 30, 2025

The Vanguard Group, Inc.

8.43M

4.88%

+334.73K

+4.13%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

Virtus LifeSci Biotech Clinical Trials ETF

1.14%

Texas Capital Texas Small Cap Equity Index ETF

0.21%

iShares Micro-Cap ETF

0.08%

Invesco Nasdaq Biotechnology ETF

0.06%

ProShares Ultra Nasdaq Biotechnology

0.06%

Texas Capital Texas Equity Index ETF

0.05%

iShares Biotechnology ETF

0.03%

iShares Russell 2000 Growth ETF

0.03%

ProShares UltraPro Russell2000

0.01%

iShares Morningstar Small-Cap ETF

0.01%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción1.14%

Texas Capital Texas Small Cap Equity Index ETF

Proporción0.21%

iShares Micro-Cap ETF

Proporción0.08%

Invesco Nasdaq Biotechnology ETF

Proporción0.06%

ProShares Ultra Nasdaq Biotechnology

Proporción0.06%

Texas Capital Texas Equity Index ETF

Proporción0.05%

iShares Biotechnology ETF

Proporción0.03%

iShares Russell 2000 Growth ETF

Proporción0.03%

ProShares UltraPro Russell2000

Proporción0.01%

iShares Morningstar Small-Cap ETF

Proporción0.01%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos